• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Field Trip Health Ltd.

    8/15/22 8:16:29 PM ET
    $FTRP
    Get the next $FTRP alert in real time by email
    6-K 1 tm2220811d2_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13A-16 OR 15D-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2022

     

    Commission File Number 001-40635

     

     

     

    Reunion Neuroscience Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    N/A

    (Translation of Registrant’s name)

     

    30 Duncan Street, Lower North Suite

    Toronto, Ontario

    M5V 2C3
    1-833-833-1967

    (Address and telephone number of registrant’s principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    Form 20-F   ¨             Form 40-F   x

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

     

     

     

     

     

     

    DOCUMENTS INCLUDED AS PART OF THIS REPORT

     

    Exhibit  
       
    99.1 Unaudited Condensed Interim Consolidated Financial Statements for the three months ended June 30, 2022 and 2021.
       
    99.2 Management’s Discussion and Analysis for the three months ended June 30, 2022 and 2021.
       
    99.3 News Release, dated August 15, 2022.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Reunion Neuroscience Inc.
         
    Date: August 15, 2022 By: /s/ Donna Wong
        Name: Donna Wong
        Title: Chief Financial Officer

     

     

     

    Get the next $FTRP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTRP

    DatePrice TargetRatingAnalyst
    11/22/2021$20.00 → $25.00Buy
    HC Wainwright & Co.
    9/1/2021$20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $FTRP
    Leadership Updates

    Live Leadership Updates

    See more
    • Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

      TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral Sciences at the School of Medicine at the University of Virginia, has joined its Scientific Advisory board. Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecu

      9/9/21 7:30:00 AM ET
      $FTRP

    $FTRP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Field Trip Health with a new price target

      HC Wainwright & Co. reiterated coverage of Field Trip Health with a rating of Buy and set a new price target of $25.00 from $20.00 previously

      11/22/21 6:28:20 AM ET
      $FTRP
    • HC Wainwright & Co. initiated coverage on Field Trip Health with a new price target

      HC Wainwright & Co. initiated coverage of Field Trip Health with a rating of Buy and set a new price target of $20.00

      9/1/21 6:13:30 AM ET
      $FTRP

    $FTRP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

      TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or "Reunion"), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "REUN" at the opening of the market on August 17, 2022. Trading of the Company's shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company's former subsidiary, Field Trip Health & Wellness Ltd. ("FTHW") into a stand-alone

      8/16/22 12:46:16 PM ET
      $FTRP
    • Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

      Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

      8/15/22 5:09:58 PM ET
      $FTRP
    • Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

      - Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN"- Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol "FTHW" - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022 - Field Trip Health & Wellness Ltd. completes $19.9 million private placement financing TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.) (TSX:FTRP, NASDAQ:FTRP) (the "Company"), and Field Trip Health &

      8/11/22 4:28:21 PM ET
      $FTRP

    $FTRP
    SEC Filings

    See more
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      1/9/23 7:35:40 AM ET
      $FTRP
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      1/4/23 4:32:30 PM ET
      $FTRP
    • SEC Form 6-K filed by Field Trip Health Ltd.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      11/28/22 4:55:14 PM ET
      $FTRP

    $FTRP
    Financials

    Live finance-specific insights

    See more
    • Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

      Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy

      8/15/22 5:09:58 PM ET
      $FTRP
    • Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 16, 2022, at 8:30 AM ET

      TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc

      8/8/22 8:00:00 AM ET
      $FTRP
    • Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

      Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi

      6/29/22 10:00:50 PM ET
      $FTRP